Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
Type 2 Diabetes Mellitus

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus
Eligibility Criteria
Inclusion criteria :
- 18 to 65 years old.
- Type 2 diabetes patients insufficient controlled by 1-3 oral anti-hyperglycemic drugs (OADs) with stable dose at least 3 months:
If on 1 OAD, provided with the following doses (including but not limited to):
- α-glucosidase inhibitor: 100mg, three times a day (tid);
- metformin: 1.5-2.0 g/day;
- sulphonylureas: sub-maximum (half dose above) to maximum tolerated dose;
- thiazolidinediones: eg. pioglitazone, 30-40 mg/day.
- Besides the medications listed above, if on 1 OAD, others should be maximum tolerated dose allowed in package insert.
- If on 2-3 OADs, any range of dose is acceptable.
- HbA1c >7%, and ≤10.5%.
- FPG >7 mmol/L.
- Body mass index (BMI) ≥20 kg/m^2, and ≤40 kg/m^2.
- Diabetes duration ≥1 year.
- Physician decides to and the patient is willing to start basal insulin (BI) treatment.
- Willing to join the study and sign the informed consent.
Exclusion criteria:
- Type 1 diabetes patients.
- Patients with acute diabetic complications (including unexplained severe hypoglycemia in the last 6 months).
- Previous treatment with insulin for more than 1 month cumulatively in last 1 year, or treatment with insulin in the last 3 months before the screening.
- Known hypoglycemia unawareness or recurrent hypoglycemia.
- Hypersensitivity to study drug or its excipients.
- Any clinically significant acute major organ or systemic disease, or any other situation judged by the Investigator, that is difficult for the 24 weeks follow-up.
- Pregnancy or breastfeeding women.
- Have any mental disorders, lack self-control or not able to express accurately.
- Involved in another clinical trial simultaneously or within a 1 month before start of trial.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Sites / Locations
- Investigational Site Number 156053
- Investigational Site Number 156001
- Investigational Site Number 156002
- Investigational Site Number 156006
- Investigational Site Number 156013
- Investigational Site Number 156014
- Investigational Site Number 156022
- Investigational Site Number 156017
- Investigational Site Number 156034
- Investigational Site Number 156023
- Investigational Site Number 156026
- Investigational Site Number 156029
- Investigational Site Number 156028
- Investigational Site Number 156040
- Investigational Site Number 156039
- Investigational Site Number 156038
- Investigational Site Number 156042
- Investigational Site Number 156044
- Investigational Site Number 156048
- Investigational Site Number 156050
- Investigational Site Number 156011
- Investigational Site Number 156052
- Investigational Site Number 156016
- Investigational Site Number 156041
- Investigational Site Number 156020
- Investigational Site Number 156018
- Investigational Site Number 156019
- Investigational Site Number 156031
- Investigational Site Number 156043
- Investigational Site Number 156049
- Investigational Site Number 156035
- Investigational Site Number 156036
- Investigational Site Number 156047
- Investigational Site Number 156027
- Investigational Site Number 156015
- Investigational Site Number 156054
- Investigational Site Number 156007
- Investigational Site Number 156010
- Investigational Site Number 156055
- Investigational Site Number 156037
- Investigational Site Number 156033
- Investigational Site Number 156030
- Investigational Site Number 156032
- Investigational Site Number 156025
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Group 1
Group 2
Group 3
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=5.6 mmol/L
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=6.1 mmol/L
Insulin glargine will be administered once daily at bedtime (preferably between 9:00 PM and 11:00 PM) by subcutaneous injection in the abdomen (preferred route) with FPG target of <=7.0 mmol/L